Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEN trial of atazanavir/ritonavir versus nevirapine with tenofovir/emtricitabine in treatment-naive HIV-1 infection
2005-004330-40Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Atazanavir/ritonavir + emtricitabine + tenofovir disoproxil with Nevirapine + emtricitabine + tenofovir disoproxil (2 arms). Primary endpoint: Treatment response at Week 48. Started Jul 2006; status: completed.
02
Drugs
atazanavirritonavirnevirapineemtricitabinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-004330-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004330-40.